Issue #39June 1, 20267 studies

AI-designed gene editor cuts off-target mutations by 553-fold

Gene editing just got a major precision upgrade. This week brought breakthrough advances in making CRISPR safer, more efficient, and applicable to diseases from atherosclerosis to traumatic brain injury.

🤖 AI designs ultra-precise gene editor that slashes off-target cuts

OpenCRISPR-1, an AI-designed gene editor, maintained Cas9-level efficiency while reducing off-target mutations by up to 553-fold compared to standard Cas9
The editor worked across 28 different genomic targets in human cells and sustained robust editing with multiple guide RNA formats
When converted into a prime editor for precise DNA changes, OpenCRISPR-1 achieved comparable editing rates while lowering unwanted edits by up to 97%

Why it matters: Off-target cuts have been a major safety concern blocking clinical gene editing applications. This AI-designed editor appears to solve the longstanding trade-off between editing power and precision.

🥇 Top 1% journal 🔗 Genome medicine Journal Article 🗓️ May 27

Key Findings

💊 Single-dose gene therapy prevents atherosclerosis in mice

Researchers developed a polymer that delivers gene editors specifically to liver cells, editing the ANGPTL-3 gene after just one treatment
In atherosclerosis-prone mice, this single dose produced sustained reductions in bad cholesterol and significantly reduced plaque formation
The polymer uses galactose to target liver cells and breaks down via natural cellular processes to release the editor directly into the cytoplasm

💡 Could point toward a one-time treatment approach for preventing heart disease rather than daily medications.

🥉 Top 5% journal 🔗 Biomaterials Journal Article 🗓️ May 29

🧠 Nasal gene therapy reduces brain inflammation after injury

Lipid nanoparticles carrying CRISPR components were delivered through the nose to target brain cells after traumatic injury
The treatment specifically edited MAPK9 in microglia (brain immune cells) and significantly reduced inflammatory responses
Intranasal delivery achieved efficient brain penetration with no detectable toxicity in major organs

💡 Suggests a non-invasive way to dial down harmful brain inflammation that contributes to long-term problems after head injuries.

🔗 Research square Preprint 🗓️ May 25

🩸 Gene editing corrects severe immune deficiency in patient cells

Scientists successfully corrected SCID-X1, a severe immune deficiency, in patient stem cells using CRISPR-Cas9
The "cut-site" approach achieved superior repair rates and lower toxicity compared to full gene replacement
Corrected cells from two SCID-X1 patients successfully developed into functional T cells in lab tests

💡 May offer a universal gene therapy approach for this severe immune disorder that currently requires risky bone marrow transplants.

🥉 Top 5% journal 🔗 Molecular therapy. Nucleic acids Journal Article 🗓️ May 25

🎯 Drug-controlled gene editing system enhances safety and precision

The PRINCE system uses small molecules to control both the gene editor protein and guide RNAs, enabling precise timing of edits
In mouse models, drug-activated editing reduced cholesterol by 45-47% and significantly improved eye disease symptoms
The controlled system showed consistently lower off-target activity compared to always-on editors, regardless of delivery method

💡 Could make gene therapies much safer by allowing doctors to control exactly when and how much editing occurs.

🥇 Top 1% journal 🔗 Science translational medicine Journal Article 🗓️ May 27

🔬 Compact gene editor works efficiently in bird cells

Cas12f, a much smaller gene editor than Cas9, achieved up to 40% editing efficiency in chicken cells with no detectable toxicity
The compact size enables better delivery into cells while producing mainly deletions rather than random insertions
Off-target analysis revealed minimal unwanted cuts, making it potentially safer for agricultural applications

💡 Opens new possibilities for improving poultry through genetic engineering with better delivery and safety profiles.

🔗 Poultry science Journal Article 🗓️ May 29

💉 Gene editing reduces blood fats by targeting liver receptor

Editing the ASGR1 gene in mouse livers achieved 54.7% editing efficiency and significantly lowered cholesterol and triglycerides
The treatment worked by modulating how the liver processes and eliminates cholesterol
In human liver cells, the same approach achieved over 91% editing with near-complete protein knockout

💡 Suggests a potential gene therapy approach for managing high cholesterol that could complement or replace daily medications.

🥈 Top 2% journal 🔗 Mol Ther Journal Article 🗓️ May 27

Implications

This week's advances suggest gene editing is rapidly maturing from a research tool into precise medical interventions. The combination of AI-designed editors, targeted delivery systems, and drug-controlled activation could address the major safety and efficacy barriers that have limited clinical applications.

Studies in this issue

Primary sources used for this newsletter.

Accurate genome and prime editing using the AI-designed openCRISPR-1 system
main storyGenome medicine2026-05-27PMID 42192532
A dual-action molecule enables precise liver cell gene editing for one-time atherosclerosis treatment
key findingBiomaterials2026-05-29PMID 42214211
Using CRISPR gene editing to fix SCID-X1 in human blood stem cells
key findingMolecular therapy. Nucleic acids2026-05-25PMID 42181695
Using gene editing on a liver protein lowers blood fat levels in mice
key findingMolecular therapy : the journal of the American Society of Gene Therapy2026-05-27PMID 42198846
Compact Cas12f allows genome editing in bird cells
key findingPoultry science2026-05-29PMID 42214263
Nasal delivery of gene-editing nanoparticles targeting MAPK9 may reduce brain inflammation after injury
key findingResearch square2026-05-25PMID 42183388
Using small-molecule drugs to control and improve precision of therapeutic genome editing in living cells
key findingScience translational medicine2026-05-27PMID 42202045